

Resource Summary Report

Generated by [dkNET](#) on Aug 3, 2026

CD3-APC, human

RRID:AB_2657063

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-109-462, RRID:AB_2657063

Antibody Information

URL: http://antibodyregistry.org/AB_2657063

Proper Citation: Miltenyi Biotec Cat# 130-109-462, RRID:AB_2657063

Target Antigen: CD3

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 6-2018; Target Distribution leukocytes, NK cells, T cells, thymocytes, T helper cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-135. (RRID:AB_2725963).

Antibody Name: CD3-APC, human

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: REA613

Antibody ID: AB_2657063

Vendor: Miltenyi Biotec

Catalog Number: 130-109-462

Record Creation Time: 20250820T025434+0000

Record Last Update: 20250820T145011+0000

Ratings and Alerts

No rating or validation information has been found for CD3-APC, human.

Warning: Discontinued: 2021

Discontinued: 6-2018; Target Distribution leukocytes, NK cells, T cells, thymocytes, T helper cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-135. (RRID:AB_2725963).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Bedrosian ZK, et al. (2025) NKG2D ligand expression on NK cells induces NKG2D-mediated cross-tolerization of cytokine signaling and reduces NK cell tumor immunity. Journal of immunology (Baltimore, Md. : 1950), 214(6), 1410.

Nehama D, et al. (2019) B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine, 47, 33.